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Abstract: In	the	late	90’s	there	was	a	change	in	both	the	route	of	transmission	and	the	people	at	risk	for	sporotrichosis.	This	
zoonotic	cat-man	alternative	transmission	route	elicited	changes	in	strategies	to	control	the	epidemic.		There	was	a	progressive	
increase	 in	 the	 number	 of	 cases	 involving	 especially	 children	 and	 the	 elderly.	 In	 addition	 to	 becoming	 hyperendemic,	
uncommon	clinical	pictures	like	immunoreactive	clinical	presentations	or	severe	systemic	cases	have	emerged.	New	species	
were	identified	and	classified	through	molecular	tools	using	more	virulent	clinical	isolates,	like	S. brasiliensis,	compared	to	the	
environmental	isolates.	Likewise,	different	species	of	Sporothrix have been associated with different geographic regions. The 
serological	and	molecular	techniques	are	used	as	an	auxiliary	tool	for	the	diagnosis	and/or	for	species	identification,	although	
the	isolation	and	the	identification	of	Sporothrix spp. in clinical specimen is still the gold standard. Currently sporotrichosis 
epidemics	requires	the	knowledge	of	the	epidemiological-molecular	profile	to	control	the	disease	and	the	specific	treatment.	
Itraconazole,	potassium	iodide,	terfinafine,	and	amphotericin	B	are	the	available	drugs	in	Brazil	to	treat	sporotrichosis.	The	
drug	of	choice,	its	posology,	and	treatment	duration	vary	according	to	the	clinical	presentation,	the	Sporothrix	species,	and	
host	immune	status.	New	treatment	choices,	including	a	vaccine,	are	being	developed;	nevertheless,	more	clinical	trials	are	
required	to	confirm	its	efficacy.
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INTRODUCTION
Sporotrichosis	is	a	subacute	or	chronic	infection,	caused	by	
thermodimorphic fungi of the genus Sporothrix. It is a cosmopolitan 
disease,	 occurring	 preferably	 in	 tropical	 and	 subtropical	 regions,	
and	is	considered	the	most	frequent	subcutaneous	mycosis	in	Latin	
America,	where	it	is	endemic.1 
Sporotrichosis	was	first	described	 in	1898,	by	 the	medical	
student	Benjamin	Schenck,	at	 the	 Johns	Hopkins	Hospital,	 in	Bal-
timore,	USA.2	 The	 fungus	 isolated	 from	 skin	 lesions	 on	 the	 right	
upper	limb	of	a	patient	treated	by	Schenck	was	evaluated	by	the	pa-
thologist	Erwin	F.	Smith,	and	identified	as	a	species	belonging	to	the	
genus Sporotrichum.	In	1900,	Hektoen	and	Perkins	reported	another	
case	in	Chicago	and	proposed	a	new	name,	Sporothrix schenckii,	al-
though Sporotrichum schenckii was used for decades.3 Due to the re-
production	characteristics	of	this	genus,	the	binomial	was	changed	
to Sporothrix schenckii.4 Currently,	the	species	involved	in	the	human	
or	animal	disease,	and	other	that	are	environmental,	have	been	rec-
ognized.5 
In	 the	 early	 20th	 century,	 in	 France,	 sporotrichosis	was	 a	
common	disease,	as		were	the	reports	of	the	extracutaneous	clinical	
forms.3	In	Brazil,	Lutz	and	Splendore	firstly	described	infections	in	
rats	and	humans,	demonstrating	the	presence	of	asteroid	bodies	in	
tissues,	which	are	useful	for	the	histopathological	diagnosis	of	this	
mycosis.6 
EPIDEMIOLOGY AND ETIOPATHOGENESIS
For	a	long	time,	sporotrichosis	was	known	as	the	“rosebush	
mycosis”,	or	the	“gardener’s	mycosis”,	given	that	the	infection	usu-
ally	 resulted	 from	 the	 agent’s	 inoculation	 on	 the	 skin	 or	mucous	
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membrane,	by	trauma	with	contaminated	plant	material.	However,	
some	cases	of	zoonotic	transmission	have	been	reported,	as	well	as	
less	frequent	cases	of	inhaled	infective	fungal	propagules,	clinically	
presenting as a systemic mycosis.7,8 
Occasionally,	there	may	be	an	environmental	transmission	
of	 sporotrichosis,	 classically	associated	with	soil	manipulation	ac-
tivities,	whether	 for	 occupational	 or	 leisure	 reasons;	 in	 outbreaks	
such	as	those	that	occurred	in	the	USA,	especially	in	the	Mississippi	
Valley,	in	the	80’s,	involving	reforestation	workers	infected	by	pine	
trees	 and	moss	 seedlings;	 also	 as	microepidemics	 like	 that	which	
occured	in	the	early	90’s,	with	people	infected	by	the	contact	with	
hay stored in an abandoned house where Halloween parties were 
held;	as	well	as	large	epidemics,	such	as	that	which		occurred	in	the	
40’s,	when	three	thousand	miners	in	South	Africa	were	infected	by	
the	contact	with	contaminated	wood	supporting	beams,	being	con-
sidered the largest epidemic in the 20th century.9-11	More	 recently,	
457 cases were described between 2007 and 2009 in a province in the 
northeast	China,	where	the	disease	is	endemic.12 
The	zoonotic	transmission	of	sporotrichosis	was	described	
sporadically	 involving	accidents	with	snakes	and	birds,	also	mos-
quito,	rat,	horse,	squirrel,	and	fish	bites.3,13,14 Epidemics were report-
ed	in	Uruguay	and,	more	recently,	in	Brazil	and	Argentina,	related	
to	armadillo	hunting,	given	the	close	relation	of	the	armadillo	with	
the soil.15,16	The	importance	of	the	cat	in	zoonotic	transmission	was	
first	noticed	when	an	outbreak	involving	five	people	exposed	to	a	
sick	animal	was	reported.17	In	Brazil,	the	main	zoonotic	sporotricho-
sis	outbreaks,	involving	humans	and	a	small	group	of	domestic	cats,	
occurred	in	the	states	of	São	Paulo	and	Rio	Grande	do	Sul,	with	an	
effective epidemiological control.18,19
In	September	1997,	the	first	cases	of	the	greatest	feline	zoo-
notic transmission epidemic ever described were admitted at the 
Pedro	 Ernesto	 University	 Hospital,	 Rio	 de	 Janeiro.	 Three	 people	
from	the	same	family	were	infected	by	a	sick	cat	that	died	(authors’	
report,	unpublished)	 (Figure	1).	Then,	 the	first	publications	about	
this	 epidemic,	which	 is	 currently	 considered	 to	 be	 hyperendemic	
in	the	state	of	Rio	de	Janeiro,	appeared.20,21 The capital city and the 
surrounding	 municipalities	 known	 as	 “Baixada	 Fluminense”	 are	
currently the most affected places where poor socioeconomic condi-
tions	are	observed.	The	epidemiological	profile	is	mainly	character-
ized	by	children,	elderly,	and	women,	because	these	groups	usually	
have	direct	and	more	frequent	contact	with	these	animals.22 Along	
with	the	consolidation	of	the	urban	epidemics,	vulnerable	patients	
also	became	a	worrisome	at-risk	population,	especially	those	infect-
ed	by	the	human	immunodeficiency	virus.23	Since	2013,	the	notifica-
tion	is	mandatory	in	the	state	of	Rio	de	Janeiro,	but	not	in	the	other	
Brazilian	states.	Therefore,	prevalence	and	incidence	measures	are	
obtained	mainly	based	on	cases	reported	in	the	literature,	certainly	
underestimating	the	real	epidemiological	importance,	especially	re-
garding	outbreaks	and	epidemics.	
Although	human	or	animal	sporotrichosis	cases	were	pub-
lished	in	the	states	of	Amazonas,	Pará,	Minas	Gerais,	Espírito	Santo,	
São	Paulo,	Rio	de	Janeiro,	Paraná,	and	Rio	Grande	do	Sul,	most	cas-
es	occur	in	the	South	and	Southeast	Brazil.24 
The	advances	in	the	microbiological	knowledge	along	with	
the use of  molecular tools led to important advances concerning 
epidemiological	studies,	enabling	the	identification	of	the	Sporothrix 
species	in	14	Brazilian	states,	indicating	that	sporotrichosis	is	more	
widespread	than	previously	thought	for	the	Brazilian	territory.24 
In	 Brazil,	 there	 are	 two	 important	 disease	 transmission	
routes	for	humans,	a	sapronotic	route	involving	direct	contact	with	
the	soil	and	decomposing	organic	matter;	and	a	zoonotic	route,	in	
which felines participate actively in the disease transmission. The 
outbreaks	from	classic	transmission	route,	in	which	S. schenckii and 
S. globosa	prevail,	required	the	removal	of	fungus	sources	in	nature.	
The	alternative	transmission	route,	mainly	involving	horizontal	ani-
mal	transmission	(cat-cat),	as	well	as	zoonotic	transmission,	requires	
different epidemic control strategies. Such measures include the 
street	animals	neutering	and	the	treatment	of	sick	cats,	as	well	as	the	
education	about	 responsible	ownership	of	 animals,	 knowledge	of	
the main aspect main aspects of Sporothrix	transmission,	especially	
in	hyperendemic	areas.	Dead	infected	animals	must	be	incinerated,	
rather	than	buried,	thus	avoiding	S. brasiliensis dissemination in the 
soil and the pathogen progression in nature.
Even though sporotrichosis has been described worldwide-
ly,	there	is	a	curious	divergence	regarding	the	geographic	distribu-
tion and the incidence of the etiological agents.25	Indeed,	some	spe-
FIgure 1: 
Ulcerated lesions on the 
hands of three members 
of	the	same	family,	at	the	
beginning	of	the	zoonotic	
transmission sporotricho-
sis epidemics in Rio de 
Janeiro,	in	1997,	treated	
at Hospital Universitário 
Pedro Ernesto
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cies	are	more	ubiquitous	than	others.	 In	Asia,	especially	China,	S. 
globosa is estimated to be the etiological agent in 99.3% of the human 
sporotrichosis cases.26,27	 In	 other	 endemic	 areas,	 such	 as	Australia	
and	South	Africa	 (94%),	also	 in	North	America	and	part	of	South	
America	(89%),	S. schenckii is the predominant species.26 In the South 
and	Southeast	Brazilian	regions,	S. brasiliensis	(88%)	is	the	main	etio-
logical agent of human and animal sporotrichosis.28,29
Over	a	century,	since	1898,	Sporothrix schenckii was described 
as	the	unique	species	responsible	for	the	sporotrichosis	cases.2,30 How-
ever,	the	advent	of	molecular	biology	techniques,	directly	applied	to	
fungus	taxonomy	researches,	demonstrated	that	the	classic	agent	S. 
schenckii actually consists	of	a	group	of	cryptic	species,	phylogeneti-
cally	related.	Currently,	Sporothrix	comprises	51	taxons,	divided	into	
a	clinical	clade	(mostly	human	pathogens),	including	S. brasiliensis,	S. 
schenckii,	S. globosa,	and	S. luriei,	an	environmental	clade,	composed	
by	some	other	species	complexes,	such	as	S. pallida and S. candida with 
five	species	each,	S.	inflata	with	three	species,	S. gossypina with 12 spe-
cies,	and	S. stenoceras	with	six	species	(Figure	2).31,32 
It is noteworthy that such a phylogenetic split is accompa-
nied	by	different	ecological	behaviors,	considering	that	S. schenckii 
and S. globosa	 have	 already	 been	 isolated	 from	humans,	 animals,	
and soil.33,34	Attempts	to	isolate	S. brasiliensis from the soil have not 
been	successful.	However,	 this	 species	 is	 frequently	 isolated	 from	
human and feline clinical samples.28,35 Sporothrix luriei is a rare hu-
man sporotrichosis agent described from a single clinical isolate in 
South	Africa.36,37	Historically,	the	overlapping	of	phenotypical	char-
acteristics	has	 led	 to	 incorrect	 identification	based	only	on	micro-
morphological analyses of environmental species. 
Environmental clade of Sporothrix species are rarely agents 
of	 human	 sporotrichosis,	 causing	 opportunistic	 infections.	 The	
infection route also involve traumatic inoculation of fungal prop-
agules present in soil and organic matter. The S. pallida complex 
consists	of	five	soil	species,	three	of	which	are	rare	agents	of	human	
infection: S. chilensis, S. mexicana, and S. pallida.38-40 The environmen-
tal clade also includes S. stenoceras	identified	from	cutaneous	lesions	
in humans.41 These environmental species are usually low-virulence 
organisms	to	the	warm-blooded,	vertebrate	host.38,42 
Sporothrix	spp.	are	thermodimorphic	fungi,	presenting	the	
filamentous	form	(saprophytic	phase)	in	nature or in vitro	at	25°C,	
and	developing	yeast-like	cells	(parasitic	phase)	in	the	mammal	host	
or in vitro at 35-37°C.43 This temperature-induced transition is an 
important morphological adaptation for the infection in mammals. 
The mycelium-to-yeast conversion occurs successfully among the 
species within the clinical clade (S. brasiliensis,	S. schenckii,	S. globosa,	
FIgure 2: 
Phylogenetic 
relations between 
the clinical and 
environmental 
clade members in 
Sporothrix,	based	
on calmodulin 
sequences	(exon	
3-5).	Available	
at	GenBank	
(https://www.
ncbi.nlm.nih.
gov/genbank/).	
Method: Maxi-
mum	likelihood	
The numbers close 
to the branches 
refer to resample 
percentages (1000 
bootstrap)
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and S. luriei),	while	the	environmental	species	(S.	inflata,	S. humicola,	
S. pallida,	S. mexicana,	S. chilensis,	among	others)	show	deficient	mor-
phological	 transition,	 producing	 few	 yeast-like	 cells.	 Perhaps,	 the	
successful emergence of S. brasiliensis	in	mammals,	as	well	as	the	low	
virulence of environmental species may be related to the thermotoler-
ance	or	thermosensitivity	of	these	species,	respectively.44	Another	im-
portant virulence factor is the Sporothrix ability to produce melanin. 
Melanin	induces	fungal	escape	from	the	host’s	defenses,	and	is	also	
considered	a	resistance	factor	against	some	antifungal	drugs,	such	as	
amphotericin	B,	itraconazole	and	terbinafine.45,46 
The	virulence	profiles	change	depending	on	the	pathogen	
characteristics and the host defenses. Sporothrix brasiliensis is the 
most	virulent	 species,	due	 to	 its	 ability	 to	 invade	 tissue	 and	 lead	
to	death,	whereas	S. schenckii has different levels of virulence and 
S. globosa exhibits little or no virulence in murine models.42,47-49 The 
environmental species of Sporothrix present low virulence in murine 
models,	with	low	invasive	potential,	and	the	host	is	able	to	control	
the	infection	a	few	weeks	after	inoculation.38,42 
           The host’s defense against the Sporothrix species 
has	not	yet	been	established.	The	fungus’	cell	wall	components,	es-
pecially	the	70kDa	glycoprotein	(gp70),	has	a	protective	effect	in	the	
host,	mediated	by	T-helper	cells	(Th1	in	humans),	but	paradoxically,	
it	also	makes	the	adherence	of	conidia	to	the	epithelium,	increasing	
fungal invasive potential. The cell-mediated immune response seems 
to	be	responsible	 for	eliminating	or	controlling	 infection.	However,	
the	humoral	immune	response	elicits	specific	antibodies	against	the	
Sporothrix’ cell wall.5,50 The dissemination of sporotrichosis is usually 
related	to	cellular	immunity	deficiencies,	such	as	AIDS.51 
CLINICAL ASPECTS
Usually,	 the	 	 clinical	 manifestations	 of	 sporotrichosis	 are	
divided	into	cutaneous	and	extracutaneous,	the	former	is	more	fre-
quent.22	After	 the	 zoonotic	 sporotrichosis	 epidemic	 in	 the	 state	 of	
Rio	 de	 Janeiro,	 new	 clinical	 presentations,	 uncommon	until	 then,	
were	identified.	For	this	reason,	a	new	classification	was	proposed,	
to better describe the clinical features of the patients cared by the 
reference sporotrichosis teams.52	 In	the	present	article,	 the	authors	
propose	an	update	of	this	clinical	classification	based	on	the	group’s	
expertise	(Table	1).
Nearly 80% of the affected patients present the lymphocu-
taneous form.52	Initially,	the	lesion	has	a	papulonodular	appearance	
where	the	fungus	was	introduced	into	the	skin,	appearing	between	
two	to	four	weeks	after	the	trauma.	Afterwards,	the	lesion	may	ul-
cerate,	and	fistulize	draining	a	purulent	discharge.	This	is	so-called	
the	 inoculation	 chancre.	 The	 lesions,	 usually	 nodules,	 progress	
along	the	regional	lymphangitic	channels,	upwards	or	downwards	
depending	 on	 the	 anatomical	 site,	 after	 some	weeks.	 Later,	 these	
nodules,	may	ulcerate,	fistulize,	and	heal,	caractherizing	a	gumma	
(Figures	3A	and	3B).	The	fixed	cutaneous	form	consists	of	a	single	
lesion,	usually	 similar	 to	 the	 inoculation	chancre,	with	no	 region-
al	lymphatic	spreading	(Figure	3C).	In	some	occasions,	the	disease	
may	appear	as	larger	ulcers	with	well-defined	and	framed	borders,	
or	 erythematous-scaly,	 papulopustular,	 vegetative,	 infiltrative,	 or	
crusty	 lesions	 (Figures	3D-F).	 Some	patients	 exhibit	multiple	 skin	
lesions,	disseminated	on	the	tegument,	with	no	systemic	 invasion	
and	polymorphic	appearance,	all	of	them	arising	at	the	same	time.	
In	general,	 these	patients	 are	 immunocompetent	 individuals	who	
describe having multiple traumas.
Although	any	mucous	membrane	may	be	affected	by	spo-
rotrichosis,	 the	 ocular	mucosa	 is	more	 commonly	 involved,	 caus-
ing	 conjunctivitis,	 episcleritis,	uveitis,	 choroiditis,	 and	 retrobulbar	
lesions,	 among	 others	 (Figure	 4A).53-55 When the lacrimal duct is 
affected,	 dacryocystitis	 may	 occur	 as	 sequela.56,57 The retrobulbar 
lesions,	such	as	chorioretinitis,	are	more	frequently	related	to	hema-
togenous	spread,	and	anterior	lesions	are	associated	with	the	fungal	
innoculation. The simultaneous affection of the ocular mucosa and 
the	regional	lymph	nodes	is	not	rare,	and	it	is	one	of	the	causes	of	
the Parinaud syndrome.58 
The	bones	and	joints	may	be	involved	by	direct	trauma,	by	
the invasion through a preexisting overlying cutaneous lesion or 
secondary	to	a	hematogenous	spreading,	the	latter	at	highest	risk	of	
sepsis due to the deep site of infection. Osteoarticular sporotrichosis 
may appear as a monoarthritis associated or not with an overlying 
cutaneous	lesions,	as	well	as	bone	resorption	and	osteolytic	lesions	
in the most severe cases.59,60	The	synovial	fluid	exhibit	increased	cel-
lularity	 mostly	 consisting	 of	 polymorphonuclear	 leukocytes,	 low	
glucose and high protein levels. 
The respiratory transmission through the inhalation of Spo-
rothrix	 propagules	 is	 acceptable,	 characterizing	 the	 primary	 pul-
monary systemic form of sporotrichosis. The lungs may also be af-
fected	by	the	hematogenous	spread,	mainly	in	immunosuppressed	
patients presenting with the disseminated systemic form of sporo-
trichosis.	The	signs	and	symptoms	may	include	coughing,	dyspnea,	
Table 1: Clinical classification of sporotrichosis  
Skin
Lymphocutaneous
Fixed cutaneous
Multiple inoculation
Mucous membrane
Ocular
Nasal
Others
Systemic
Osteoarticular
Cutaneous disseminated 
Pulmonary
Neurological
Other locations/sepsis
Immunoreactive
Erythema nodosum
Erythema multiforme
Sweet's syndrome
Reactive arthritis
Spontaneous regression
Modified	from:	Lopes-Bezerra,	et al. 2006.52
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hemoptoic,	etc,	depending	on	the	type	and	site	involved.	Radiolog-
ic	images,	such	as	chest-radiography	or	computerized	tomography,	
show	diverse	features.	The	upper	lobes	are	mostly	affected,	present-
ing	cavitary,	reticulonodular	infiltrative,	or	even	fibrosis	or	tumoral	
aspects.61-64 Probably the disease is misdiagnosed in areas with high 
endemicity,	either	due	to	the	lack	of	knowledge	by	the	medical	doc-
tors,	or	to	the	unspecific	clinical	signs	and	symptoms.65 
	The	imunosuppressed	patients	are	at	higher	risk	for	blood-
stream	 dissemination	 of	 sporotricosis	 due	 to	 alcoholism,	 or	 the	
chronic	 use	 of	 illicit	 drugs,	 the	 use	 of	 immunosuppressive	medi-
cation,	or	secondary	to	immunodeficiency	such	as	AIDS.	In	theses	
cases	 the	bones	and	 joints,	 the	 lungs	and	central	nervous	system,	
in	addition	to	the	skin	and	mucous	membranes,	are	preferably	af-
fected,	although	any	organ	may	be	involved	(Figures	3D-F).	These	
patients also show heterogenous and polymorphic tegumentary le-
sions,	and	must	have	a	special	attention	in	their	medical	care,	partic-
ularly	AIDS.	Moreover,	they	may	develop	systemic	manifestations	
that	include	severe	bone	lesions,	hematogenous	disseminated	skin	
and	mucosal	 lesions,	 lung	and	spleen	 involvement,	as	well	as	 the	
neurotropism shown by S. brasiliensis. They	may	progress	to	sepsis,	
leading to death.51,64,66	Curiously,	systemic	sporotrichosis	reports	in	
transplanted	patients	 are	 not	 frequent.	 Similar	 to	American	 tegu-
mentary	leishmaniasis,	which	is	an	important	differential	diagnosis,	
the centrofacial region is commonly affected in immunocompro-
mised	patients	(authors’	note).
FIgure 3: A.	Lymphocutaneous	form	in	adults	(ascending	lymphangitis);	B. lymphocutaneous form in a child’s  face (descending lymphan-
gitis);	C.	fixed	cutaneous	form	on	the	back	of	the	hand;	D, E, F. systemic	form	with	disseminated	skin	lesions	in	an	AIDS	patient
FIgure 4: A. Granulomatous	lesion	at	the	upper	eyelid	ocular	conjunctiva; B.	primary	lymphocutaneous	lesion	on	the	finger;	and	C. pseudove-
sicular	lesions	over	an	erythematous	plaque	on	the	back	of	the	same	patient	-	Sweet’s	syndrome	(immunoreactive	form)
A B
D E F
C
A B C
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At	the	other	end,	as	occurs	in	other	infectious	diseases,	some	
patients	heal	spontaneously,	while	others	develop	hypersensitivity	
clinical	 forms,	 such	 as	 erythema	nodosum,	 erythema	multiforme,	
and Sweet’s syndrome due to an exacerbated immune response 
against	 the	 fungus.	Also,	 reactive	 arthritis	 can	occur,	 it	 is	 usually	
polyarticular	and	migratory,	frequently	disappearing	with	the	spe-
cific	treatment	for	sporotrichosis	(Figures	4B-C).67-69
In	general,	 the	 lesions	heal	 leaving	fibrotic	scars	 that	may	
alter	the	organ	function	depending	on	the	site	of	 infection,	for	 in-
stance,	the	tear	duct	or	the	lungs.	Unaesthetic	scars	are	particularly	
important	 in	younger	patients,	 especially	 in	 exposed	areas,	 given	
that	the	disease	leads	to	fibrosis,	sometimes	causing	tissue	or	hair	
loss,	such	as	eyelashes,	in	the	case	of	bulbar	conjunctival	lesion.52
The	children,	the	elderly,	the	pregnant	women,	and	the	im-
munosuppressed	AIDS	 patients	 are	 groups	 that	 require	 a	 special	
attention.70,71	Children	generally	have	more	prolonged	and	frequent	
contact	with	animals	and,	 therefore,	are	commonly	 infected.	Nev-
ertheless,	they	also	exhibit	a	greater	immunological	resistance	with	
limited	lesions	such	as	the	fixed	form,	usually	on	the	face;	exhibiting	
slightly elevated serological titers.71 The facial contact with animals 
also predisposes this age group to ocular mucosal lesions. On the 
other	hand,	the	task	of	taking	care	of	animals	is	usually	assigned	to	
the	elderly,	especially	females.	In	this	age	group,	the	host	immune	
defense	is	declining,	which	means	that,	 in	many	times,	 there	may	
be a more extensive and severe clinical presentation of the disease.
DIFFERENTIAL DIAGNOSIS
Due	to	the	diversity	of	clinical	presentations,	sporotrichosis	
may be clinically similar to many other infectious and non-infec-
tious	diseases,	both	tegumentary	and	systemic.	The	most	common	
are	tegumentary	leishmaniasis,	pyodermitis,	cat-scratch	disease,	cu-
taneous	nocardiosis,	chromomycosis,	syphilis,	rosacea,	granuloma	
annulare,	 pyoderma	 gangrenosum,	 osteomyelitis,	 arthritis	with	 a	
different	etiology,	such	as	rheumatoid,	also	cutaneous	and	pulmo-
nary	tuberculosis,	tumoral	lesions,	especially	in	the	lungs	and	in	the	
central	nervous	system,	and	meningitis,	besides	others.	In	regions	
of	high	endemicity,	the	epidemiological	background	must	be	taken	
into consideration.
LABORATORY DIAGNOSIS
Mycology 
The gold standard for the diagnosis of sporotrichosis is the 
isolation	and	the	 identification	of	 the	Sporothrix species from clin-
ical	 samples	 such	 as	 skin	 lesions,	 biopsy,	 aspirated	 from	 floating	
abscesses,	as	well	as	sputum,	pus,	synovial	fluid,	blood,	and	cere-
brospinal	 fluid.8,72	 It	 is	 a	 simple	 and	 low-cost	 diagnostic	method,	
although it may not be useful for some systemic and atypical forms 
of sporotrichosis.52,73 
Seldom,	 the	direct	microscopy	 (DM)	made	with	potassium	
hydroxide	 (KOH)	preparations,	whether	or	not	 in	dimethyl	sulfox-
ide,	exhibits	fungal	elements.	When	present	in	the	tissue,	Sporothrix 
spp.	 show	 	 several	 yeast-like	 structures,	 oval	 to	 round,	 and	more	
commonly	elongated,	“cigar-shaped”,	measuring	approximately	5-8	
µm.74	Compared	to	the	culture,	DM	presents	low	sensitivity	and	spec-
ificity,	being		positive	in	sporotrichosis	mainly	in	immunosuppressed	
patients.75,76	Giemsa-stained	smears,	obtained	from	pus	or	biopsy	im-
prints, enhance the test’s sensitivity.8 On the other hand DM is more 
sensitive	in	animals,	particularly	felines,	due	to	the	great	amount	of	
fungal	cells	in	the	tissues,	exhibiting	sensitivity	of	nearly	85%	com-
pared to the culture.77 Sporothrix spp. grow in culture media used rou-
tinely,	at	room	temperature	(25ºC-30ºC),	such	as	Sabouraud	dextrose	
agar	with	chloramphenicol	or	gentamicin,	added	to	inhibit	bacteria;	
Mycosel	agar	containing	cycloheximide,	to	reduce	saprophytes,	and	
BHI	(Brain	Heart	Inffusion),	an	enriched	medium.8,76 Sporothrix spp. is 
usually	isolated	in	4-6	days,	for	samples	collected	from	skin	lesions,	
and	in	10-19	days,	for	extracutaneous	lesions;	time	can	also	vary	de-
pending on the species of Sporothrix.73,76,78,79 
Colonies	are	identified	phenotypically	by	the	membranous	
appearance	 of	 the	 surface,	 off-white	 to	 cream	 color	 and	 a	 black	
halo,	or	 they	may	be	dark	 from	 the	beginning,	depending	on	 the	
species,	and	on	the	nutritional	and	environmental	conditions	(Fig-
ure	5A).	The	colony	microscopy	of	the	clinical	clade	exhibit	delicate	
branched	septate	hyaline	hyphae,	a	conidiophore	producing	at	the	
tip	pyriform,	oval	to	round,	hyaline	conidia,	arranged	sympodial-
ly	 as	 a	 bouquet,	 in	 addition	 to	 sessile	 pigmented	 conidia	 (Figure	
5B).33,74 The thermodimorphism of the Sporothrix species of clinical 
FIgure 5: A. Macromorphology of Sporothrix brasiliensis;	B.	Micromorphology	reveals	delicate,	hyaline	septate	hyphae,	conidiophore	that	origi-
nates	primary	hyaline	conidia	in	a	bouquet	arrangement	(cotton	blue,	x400);	C.	Asteroid	body	(Grocott,	X400)
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interest	 is	 confirmed	 by	 reverting	 the	mycelium-to-yeast	 form	 in	
BHI,	 after	 incubation	at	 37ºC.	The	yeast-like	 colony	has	a	 creamy	
color	surface.	For	phenotypical	confirmation	of	Sporothrix species,	
other	culture	media	are	used, such as corn meal agar	 to	define	 the	
conidia	shape	and	color.	For	instance,	ovoid	dematiaceous	conidia	
suggest S. brasiliensis,	while	triangular	conidia	are	characteristic	of	
S. schenckii; it is also used to distinguish S. mexicana from S pallida.33 
In addition to the thermotolerance of the Sporothrix	isolates,	the	pota-
to dextrose agar	(PDA),	a	culture	media	poor	in	nutrients,	is	useful	in	
comparying fungal morphology and growth (measured by the col-
ony’s	diameter).	Sporothrix brasiliensis forms	dark	black	fast	grow-
ing	colonies.	Exceptionally,	Sporothrix isolates grow at temperatures 
above	37ºC,	regardless	of	the	species.
Assimilation	of	sugars	such	as	glucose,	raffinose,	ribitol,	and	
sucrose are some of the carbon compounds used in physiological 
tests;	the	Sporothrix isolates show different pattern of assimilation.79
Histopathology 
The sensitivity of histopathology test in humans is low due 
to	 the	paucity	of	 fungal	elements	 in	 the	 tissue.	The	 inflammatory	
infiltrate	 is	 better	 observed	 by	 hematoxilyn-eosin	 stain,	 and	 PAS	
or methenamine silver is used to identify the fungal structures.8 
According	 to	 the	 literature,	 fungal	 structures	 are	 present	 in	 18	 to	
35.3%	of	the	cases,	depending	on	the	technique.76,80,81 The tissue re-
action	consists	of	diffuse	chronic	granulomatous	dermatitis,	many	
times with a central abscess. The histological sections may exhibit 
hyperkeratosis,	acanthosis,	and	intraepidermal	microabscesses.	The	
granuloma	in	palisade	arrangement,	consisting	of	a	neutrophil	and	
eosinophil	 central	 area,	 an	 intermediate	 layer	 with	 mononuclear	
cells,	and	lymphocytes	and	plasmacytes	at	the	most	external	area,	
may	be	observed	in	skin	lesions.82 The presence of asteroid bodies 
or Splendore-Hoeppli phenomenon may point to the diagnosis of 
sporotrichosis. It consists of an eosinophil material surrounding the 
fungal	cell,	probably	a	deposit	of	immunoglobulin	attached	to	the	
microorganism	wall.	However,	 it	 can	 occur	 in	 other	 infectious	 or	
granulomatous	diseases	(Figure	5C).8 
Serology 
Different	 techniques	 of	 immunoelectrophoresis,	 aggluti-
nation,	and	 immunodiffusion	using	crude	antigenic	 fraction	were	
proposed	 for	 the	serodiagnosis	of	 sporotrichosis,	but	 the	sensitiv-
ity	and	specificity	were	 low.83,84	Consequently,	 they	were	 replaced	
by	more	sensitive	tests,	such	as	the	immunoenzymatics,	especially	
ELISA	(Enzyme	Linked	Immuno	Sorbent	Assay)	and	Western	blotting,	
both	with	faster	results.	The	use	of	serology,	a	fast	and	non-invasive	
test	for	the	diagnosis	of	sporotrichosis,	was	possible	when	specific	
antigens	were	characterized	and	standardized.	These	tests	are	used	
as auxiliary tools for cutaneous forms and to diagnose systemic 
manifestation or atypical forms of sporotrichosis. They are useful 
for	screening,	to	control	treatment	follow	up	and	drug	withdrawn	
in	 difficult	 clinical	 presentations.	 Serum	 antibody	 titers	may	 also	
monitor relapses.52,85-87 
Serological	ELISA	test	using	the	SsCBF (Sporothix schenckii 
Con	A-Binding	Fraction),	a	cell	wall	antigen	from	the	yeast	phase	
of S. schenckii,	has	proven	efficient	for	the	detection	of	IgG	antibod-
ies in the serum of patients with cutaneous sporotrichosis.88 Tests 
performed in serum samples of patients with different clinical spo-
rotrichosis	 forms	 resulted	 in	high	 sensitivity	and	specificity	 rates,	
90%	 and	 80%	 respectively,	 in	 addition	 to	 high	 reactivity	 in	 feline	
serum samples.85,89	ELISA	test	using	the	SsCBF exhibited reactivity 
with	other	 clinical	 specimens,	 such	as	 cerebrospinal	 and	 synovial	
fluid,	with	high	positivity	and	low	cross-reaction	rates.59,85 There is 
an effective clinical-serological correlation which allow therapeutic 
monitoring,	and	can	be	used	whether	 to	maintain	or	suspend	the	
treatment	 of	 difficult	 cases.57,67,71	An	 exoantigen	 isolated	 from	 the	
filamentous	 form	of	S. schenckii	was	used	 in	 the	ELISA	 test,	with	
97%	of	sensitivity,	and	89%	of	specificity,	when	evaluating	different	
serum samples from patients with sporotrichosis.86 
Two other important cell wall components in Sporothrix 
spp	have	been	studied	as	new	biomarkers	for	sporotrichosis	diag-
nosis,	the	glycoproteins	of	60	kDa	and	70	kDa,	identified	as	3-car-
boxy-muconate cyclase of the Sporothrix proteome, as glycoforms and 
isoforms.5 Such glycoproteins seem to behave as a factor of viru-
lence,	they	are	expressed	in	the	most	virulent	Sporothrix isolates,	and	
contribute to the fungus adherence and immunomodulation.48,90-93 
The	produced	mAb	P6E7	antibody	against	the	gp70	caused	in vivo 
protection	through	passive	immunization	of	mice	infected	with	S. 
schenckii. It is considered to be a strong candidate for a therapeutic 
vaccine against sporotrichosis.91,94
These	 tests	 are	 not	 commercially	 available,	 being	 restrict-
ed	 to	certain	research	centers,	especially	due	 to	 the	 lack	of	Public	
Health	financing	in	Brazil,	where	sporotrichosis	is	endemic	or	hype-
rendemic,	depending	on	the	country	region.
Molecular	
The	 phenotypical	 identification	 of	 the	 different	Sporothrix 
species	 have,	 as	 a	 disadvantage,	 the	 use	 of	 tools	 that	 are	 usually	
laborious,	 longstanding,	 with	 variable	 results,	 especially	 for	 the	
species	inserted	in	the	clinical	clade,	which	could	lead	to	incorrect	
identification.39,95-97	Nowadays,	the	molecular	boundaries	among	the	
Sporothrix	spp.	are	defined,	enabling	the	development	of	numerous	
genetic	markers	for	recognition	and	identification	of	clinical	speci-
mens.44 The development of fast and low-cost genotyping methods 
is	 important	 for	diagnosis,	 as	well	as	 for	epidemiological	 studies,	
considering that the pathogenic species in Sporothrix differ in terms 
of	their	geographical	range,	virulence,	and	susceptibility	to	antifun-
gal drugs. 
DNA	 sequencing	 -	 PCR	 (Polymerase	 Chain	 Reaction)	 tech-
nique.	The	identification	of	Sporothrix	isolates	with	clinical	interest,	
which	frequently	 infect	 the	vertebrate	host,	may	be	performed	by	
the	amplification	and	partial	 sequencing	of	 ribosomal	operon,	 in-
cluding	the	ITS1,	5.8s,	and	ITS2	regions.	The	ITS	(Internal	Transcript	
Spacer)	region	operates	as	a	universal	marker	for	the	identification	
of Sporothrix.31 The human and animal origin specimens are distrib-
uted in the S. brasiliensis,	S. schenckii,	S. globosa,	and	S. luriei clades.32 
The environmental Sporothrix species are located at a relatively large 
phylogenetic	distance.	However,	it	is	worth	noticing	that,	in	the	en-
vironmental	clade,	in	addition	to	the	ITS	region,	the	use	of	protein	
coding	genes	for	the	recognition	of	cryptic	species,	especially	in	the	
S. pallida complex, will	be	required.38 Protein	coding	genes,	such	as	
the beta-tubulin (BT2),	 calmodulin	 (CAL),	 and	 the	elongation	 fac-
tor 1α (EF-1α)	may	be	used	 to	 increase	 the	 taxonomic	resolutions	
among	the	clinical	 interest	species,	or	even	to	 identify	rare	agents	
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within the S. pallida	complex,	in	the	environmental	clade,	such	as	S. 
pallida,	S. mexicana,	and	S. chilensis. The region between the 3 and 5 
exons	of	the	calmodulin	gene	appears	as	the	main	marker	for	recog-
nition of clinical interest Sporothrix.98-101 In addition to the possibility 
of	 identifying	 the	 infectious	agent,	protein-coding	genes	are	com-
monly	 used	 in	 studies	 on	 genetic	 diversity,	 population	 structure,	
and molecular epidemiology of sporotrichosis.29
PCR-RFLP -	 the	 amplification	 of	 a	 target	 sequence	 in	 the	
fungus	genome	by	means	of	PCR,	followed	by	amplicon	digestion	
with	one	or	a	combination	of	restriction	enzymes	(RFLP),	has	been	
successfully	used	to	detect	inter-	and	intra-specific	variability	in	sev-
eral fungus species. In clinical interest Sporothrix	spp.,	the	identifi-
cation of morphologically similar species becomes possible with the 
use	of	PCR-RFLP.	After	the	partial	amplification	of	the	calmodulin	
gene	(exon	3-5),	the	amplicon	digestion	with	the	HhaI	enzyme	takes	
place,	producing	five	different	restriction	profiles	(species-specific),	
representing all species with medical importance.102 Some important 
advantages	of	this	technique	include	low-cost,	fast	and	easy	execu-
tion,	associated	with	the	absence	of	need	for	advanced	instruments.
Species-specific	PCR	 -	 the	 identification	of	Sporothrix spp. 
may	be	performed	by	means	of	PCR,	by	using	primers that selective-
ly	amplify	DNA	from	S. brasiliensis,	S. schenckii,	S. globosa,	S. mexi-
cana,	S. pallida,	and	S. stenoceras.103	Therefore,	the	primer	sequences	
are	preserved	within	a	single	target	species	and	inter-specifically	di-
vergent.	This	technique	is	a	low-cost,	fast	and	robust	molecular	tool,	
capable	of	detecting	and	identifying	small	pathogen	DNA	based	on	
isolated	specimens,	as	well	as	complex	biological	samples	(biopsy,	
soil,	mixed	cultures,	etc.),	with	no	need	to	isolate	the	pathogen.
Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics 613
An Bras Dermatol. 2017;92(5):606-20.
Rolling	Circle	Amplification	 (RCA)	 is	 a	method	 that	 pro-
vides	high	sensitivity	and	robustness,	which	may	be	applied	from	
monosporic	cultures	 to	environmental	samples,	with	potential	 for	
ecology studies.104	The	identification	of	Sporothrix	based	on	RCA	has	
proven	 to	 be	 a	 reliable	 identification	 tool,	 alternative	 to	DNA	 se-
quencing,	although	little	used	in	the	mycological	diagnosis,	despite	
being	 a	 simple	 and	 powerful	 technique,	 capable	 of	 synthesizing	
large	DNA	amounts	based	on	very	low	initial	concentrations.104,105
Figure	 6	 represents	 a	 flowchart	 that	 synthesizes	 the	 tech-
niques	used	for	laboratory	diagnosis	of	sporotrichosis.
TREATMENT 
The choice of treatment for sporotrichosis depends essen-
tially	on	the	clinical	form	of	the	disease,	the	host’s	immunological	
status,	and	the	species	of	Sporothrix involved. 
Drug
Itraconazole,	potassium	iodide,	terbinafine,	and	amphoter-
icin	B	are	the	drugs	currently	available	in	Brazil	for	treating	sporo-
trichosis.	The	first	three	are	administered	orally,	while	the	last	one	is	
administered intravenously. 
Itraconazole	is	considered	the	drug	of	choice	due	to	its	effec-
tiveness,	safety,	and	posologic	convenience,	and	it	is	classified	hav-
ing	an	AII	scientific	evidence	level.72,106 It is a fungistatic drug that 
acts by inhibiting the synthesis of ergosterol in the fungus cell wall. 
It	may	be	used	in	healthy	patients	with	limited	lesions,	as	well	as	
in	immunosuppressed	patients	and	in	the	systemic	form,	but	not	in	
life-threatening cases of dissemination/sepsis. It is offered in 100mg 
capsules	and	must	be	administered	along	with	the	main	meals,	for	
better	absorption.	The	dose	ranges	from	100	to	400mg/day,	depend-
ing on the disease severity. The treatment should be started with 
100mg/day,	which	is	effective	in	most	cases.	It	may	be	administered	
continuously	or	 intermittently	 (pulse).107 The main adverse effects 
reported	are	headache	and	gastrointestinal	disorders,	which	are,	in	
most	cases,	tolerable.	It	is	hepatotoxic,	teratogenic,	and	embryotox-
ic,	and	may	not	be	used	in	patients	with	liver	diseases	or	in	pregnant	
women	(risk	category	C).	Its	greatest	disadvantage	is	the	possibility	
of	drug	interaction,	as	a	consequence	of	the	dependent	metabolism	
on	CYP	3A4	common	 to	other	 several	drugs.	 It	may	cause	an	 in-
crease	or	a	reduction	of	serum	drug	concentrations	frequently	used	
by	 elderly	patients	usually	 affected,	 also	 these	drugs	may	 reduce	
or	increase	serum	itraconazole	levels.	Childbearing	women	must	be	
warned	about	the	risk	of	oral	contraceptive	effect	reduction.	In	ad-
dition,	there	is	a	risk	of	sudden	death,	especially	in	patients	suffer-
ing	from	congestive	heart	failure,	due	to	its	negative	inotropic	effect	
on the cardiac muscle.108	Complete	blood	count,	biochemistry,	and	
liver function tests should be performed prior to the treatment and 
after	3-4	weeks.	If	serum	levels	are	whithin	normal	ranges,	the	tests	
should only be repeated at the end of the treatment. 
Potassium	 iodide	 (KI)	 has	 been	 used	 for	 treating	 sporo-
trichosis,	 since	 1903,	 as	 initially	 suggested	 by	 Saboraud.7	At	 that	
time,	specific	antifungal	drugs	were	not	available	and	 iodide	was	
used for several infectious and non-infectious diseases. The KI 
mechanism	of	action	is	not	yet	completely	understood,	despite	its	
already	known	action	on	the	immune	response,	destructuring	gran-
ulomas,	 on	 neutrophil	 chemotaxis,	 as	well	 as	 on	 phagocytosis	 of	
FIgure 6: Flowchart for laboratory diagnosis of sporotrichosis. GMS 
(Gomori methenamine silver);	CMA	(corn	meal	agar);	‘C’	–	carbon;	
ITS (Internal	Transcript	Spacer);	PCR	(Polymerase	Chain	Reaction)
Sporothrix cells.109,110	The	scientific	evidence	level	is	AII,	the	same	of	
itraconazole,	and	it	may	be	prepared	as	saturated	or	concentrated	
solution.	 In	 the	 saturated	 solution,	 each	drop	 contains	 0.07g,	 and	
in	 the	concentrated	solution,	0.05g.111 Doses of up to 4-6g/day for 
adults	are	recommended.	However,	a	recent	study	has	demonstrat-
ed	that	doses	of	1-2g/day	for	children,	and	2-4g/day	for	adults,	ad-
ministered	t.i.d	with	milk,	juice	or	yogurt	are	effective	to	cure	most	
patients.112	The	treatment	starts	with	lower	doses,	increasing	daily	
in	both	intakes	until	the	effective	and	tolerated	dose	is	reached.	This	
is	especially	useful	for	the	elderly	and	for	children,	as	it	is	available	
in	the	liquid	form.	KI	is	indicated	for	localized	sporotrichosis	cases	
in	patients	whose	immunity	is	preserved,	but	it	may	also	be	used	
in	 immunoreactive	 forms,	 such	as	 erythema	nodosum	or	 reactive	
arthritis,	due	to	its	immunomodulatory	effect.	It	is	contraindicated	
for	patients	with	thyroid	dysfunction,	kidney	failure,	iodine	allergy,	
autoimmune	diseases,	 and	 in	 pregnant	 and	nursing	women	 (risk	
category	D).	Up	 to	now,	 it	 is	not	 indicated	 for	patients	who	have	
deficiency	of	 immune	response,	and	extensive	or	systemic	clinical	
manifestations. The main adverse events are metallic taste and nau-
sea,	followed	by	acneiform	eruption.	In	addition	to	the	laboratory	
tests	for	monitoring	itraconazole	use,	for	KI	it	is	important	to	check	
the	TSH	and	T4	 serum	 levels	during	 treatment,	 although	a	 slight	
increase in TSH serum levels is considered to be physiological.111
	Terbinafine,	a	fungicide	allylamine	that	inhibits	the	synthe-
sis	of	ergosterol	in	the	fungus	cell	wall,	is	an	excellent	therapeutic	
option	for	patients	with	contraindications	to	itraconazole	or	KI	use,	
as its effectiveness in the sporotrichosis treatment is well demon-
strated.113,114	This	medication	 is	metabolized	 through	 the	CYP2D6,	
which	 is	 not	 involved	 in	many	 other	 drugs,	 thus	 it	 exhibits	 few-
er	drug	interactions,	and	it	is	especially	useful	for	elderly	patients	
with other comorbidities. It is available in tablets of 125 and 250 mg 
facilitating pediatric administration. The recommended dose is 250 
mg/day,	but	it	may	be	increased	up	to	500	mg/day	for	adults.	The	
pediatric dose depends on the child’s weight and is the same rec-
ommended	for	treating	dermatophytosis.	It	may	cause	headaches,	
nausea,	 taste	 alteration,	 and	 neutropenia.	 Terbinafine	 is	 contrain-
dicated	 for	patients	with	 lupus	 erythematosus,	 and	 is	 considered	
a	risk	category	B	drug	during	pregnancy.	Its	use	has	not	yet	been	
tested for other clinical forms other than the cutaneous. The labora-
tory exams are the same as those for monitoring the treatment with 
itraconazole.
	 In	 severe,	 life-threatening	 cases,	 amphotericin	 B,	 deoxy-
cholate	 or,	 preferably,	 liposomal,	 is	 recommended	 until	 the	 clin-
ical	 improvement	has	been	 achieved,	when	 it	 should	be	 replaced	
by	 itraconazole.72	 Amphotericin	 B	 is	 a	 polyene	 that	 links	 to	 the	
ergosterol	of	 fungal	membrane,	modifying	 its	permeability.	When	
administered	 intravenously,	 amphotericin	 B	 is	 cardiotoxic	 and	
nephrotoxic,	thereby	requiring	constant	evaluation	of	kidney	func-
tion and of the serum potassium levels. The total cumulative dose 
recommended	ranges	 from	1	 to	3g	 for	deoxycholate	presentation,	
or the corresponding liposomal dose. The precautions and types of 
amphotericin B administration for sporotrichosis treatment are the 
same as those used in other mycoses for which the drug is indicated. 
This is the only drug recommended for pregnant women with se-
vere	disease,	given	that	it	is	not	teratogenic,	although	it	may	worsen	
metabolic disorders that are already common during pregnancy. 115
 Sporotrichosis treatment must be maintained until the clin-
ical	cure	is	reached,	which	usually	occurs	within	2	to	3	months.	It	is	
not necessary to maintain the drug use for 1 to 3 months after the 
cure,	as	previously	recommended.	Clinical	cure	is	considered	when	
there	is	no	disease’s	activity,	such	as	pus,	exsudation,	or	crust	in	the	
skin	 lesions,	 even	 if	 a	discrete	 erythema,	fibrosis,	 or	milia	 appear	
during	 the	 healing	 process.	 Systemic	 forms	 require	 longer	 treat-
ment,	ranging	from	6	to	12	months.72
 Miscellaneous 
The	local	heat	was	initially	used	to	treat	chromomycosis,	it	
is	based	on	the	fungus’	thermosensitivity,	and	may	be	useful	when	
conventional drugs are contraindicated.115,116	Cryosurgery	using	liq-
uid nitrogen may be used as a therapeutic complement in refractory 
cases,	 especially	when	 lesions	are	 crusty	 and	 infiltrate,	 as	well	 as	
in	isolated	cases	of	localized	lesions	in	immunocompetent	patients.	
Electrosurgery and surgical removal of small lesions constitute oth-
er	 therapeutic	 options	 in	 selected	 cases.	All	 therapeutic	methods	
described	may	be	used	as	monotherapy	or	as	adjuvant	treatment.	
Photodynamic therapy was tested in vivo and in vitro for the treat-
ment	of	skin	sporotrichosis.117
 Figure 7 shows basic steps to guide the therapeutic choice in 
sporotrichosis,	and	table	2	provides	the	summary	of	the	main	drugs	
administered in sporotrichosis and their corresponding doses.
 Other considerations
There are important differences regarding in vitro sensitivity 
to	 the	main	 antifungal	 drugs	 and	 the	different	 etiological	 agents,	
reinforcing	the	importance	of	the	correct	identification	for	proper-
ly treating sporotrichosis. Sporothrix brasiliensis presents the best 
response	 to	 antifungal	 drugs,	 while	 S. mexicana is more tolerant 
to drug action.118 Epidemiological analyses reveal that the in vitro 
susceptibility	profile	has	been	changing	over	time,	emphasizing	the	
emergence of S. brasiliensis	isolates	tolerant	to	itraconazole.119 In this 
context,	potassium	iodide,	terbinafine,	and	posaconazole	may	be	al-
ternative drugs against S. brasiliensis,	especially	in	refractory	cases,	
or for those with no satisfactory in vivo	response	to	itraconazole.96,112 
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FIgure 7:	Algorithm	 for	 the	 treatment	 of	 sporotrichosis.	 LC	 –	 lym-
phocutaneous;	CF	–	fixed	cutaneous;	KI	–	potassium	 iodide;	 ITZ	–	
itraconazole;	TBF	–	terbinafine;	AmB	–	amphotericin	B
Modified from: Orofino-Costa,	et	al.	201570
1Hyperkeratotic	or	 refractory	 cutaneous	 lesions:	heat,	 cryosurgery,	 electrosurgery,	 exci-
sion/drainage,	Kl	+	ITZ	or	Kl	+	TBF
2Children,	elderly,	immunoreactive	forms:	Kl
Pregnant	women:	Heat,	cryosurgery,	AmB
KI	 has	 been	 used	 in	 association	 with	 itraconazole,	 for	 refractory	
mycosis	in	felines.	However,	its	use	in	immunosuppressed	humans	
needs to be better evaluated due to the possibility of changes in the 
immunological	 reactivity,	 and	 worsening	 of	 the	 underlying	 dis-
ease.120 This association has been used in humans with conidiobo-
lomycosis.121 The effectiveness of this combination of drugs is prob-
ably due to the different mechanisms of action and synergism of 
both drugs. KI capsules still needs to be tested in humans regarding 
absorption,	pharmacodynamics,	and	bioavailability	for	the	effective	
dose	adjustment	in	the	treatment	of	sporotrichosis.	
	The	drugs	5-fluorocytosine,	caspofungin,	and	fluconazole	do	
not exhibit in vitro antifungal activity against S. brasiliensis,	S. schenckii,	
S. globosa,	or	S. mexicana.122,123	In	vitro	analyses	indicate	significant	dif-
ferences	among	the	minimum	concentrations	required	to	inhibit	the	
growth of Sporothrix	 spp.	and	 the	required	concentration	 to	reduce	
the	number	of	 colony-forming	units,	demonstrating	 the	 fungistatic	
and non-fungicide effect for the most available antifungal drugs.
PROGNOSIS
Immunocompetent	 individuals	with	skin	or	mucosal	 clin-
ical	forms	usually	heal	 in	a	short	period	of	time,	although	fibrous	
scars	are	frequent	complaints	leading	to	functional	or	unesthetic	se-
quelae.	In	immunosuppressed	patients,	especially	AIDS,	the	disease	
may disseminate and cause death. Untreated patients with chronic 
skin	lesions	may	develop	severe	clinical	forms,	with	systemic	mani-
festations,	frequently	requiring	inpatient	treatment.
PERSPECTIVES
For	over	a	century,	sporotrichosis	was	described	as	an	oc-
cupational	disease,	with	a	strong	rural	profile.	However,	in	the	last	
decades Sporothrix spp. as a threat to the warm-blooded vertebrate 
hosts’ health has emerged. The close relation between S. brasiliensis 
and	the	 feline	host	 is	curious,	 so	 that	 it	 causes	 large	epizooties	 in	
urban areas.124	 Indeed,	 zoonotic	 pathogens	 are	more	 often	 associ-
ated	 with	 emerging	 diseases	 than	 the	 non-zoonotic	 pathogens.125 
This indicates the need to investigate the S. brasiliensis’ transmission 
dynamics involving cats and humans. Such a transmission route 
(cat-man)	broke	a	paradigm	in	a	disease	in	which	epidemiology	had	
already	been	considered	to	be	resolved,	to	a	large	extent.	Ecological	
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studies	are	important,	given	that	the	uncertainty	regarding	the	fun-
gus’	reservoirs	in	the	environment	and	reasons	for	the	fluctuation of 
Sporothrix population still exists. 
The	knowledge	of	the	epidemiological-molecular	profile	is	
essential	 to	understand	 the	dynamics	 of	 species	 occurrence,	 from	
the	standpoint	of	both	the	characterization	of	a	differentiated	clin-
ical	standard	and	the	response	to	the	treatment,	as	well	as	the	im-
plementation of strategic Public Health policies intended to control 
epidemics. The low-cost molecular methods are important because 
they	provide	fast	and	accurate	results,	particularly	during	disease	
outbreaks.	 However,	 for	 countries	 with	 limited	 health	 budgets,	
isolating the Sporothrix in culture media is still the best diagnostic 
method,	concerning	both	cost	and	positivity.
Investigations on the host-parasite interaction have evolved 
regarding	both	cell	and	humoral	immune	responses.	However,	re-
cent researches involving 3-carboxy-muconate cyclase (gp60-gp70)	
and	the	humoral	activity	reconducted	the	seek	for	specific	antigens	
that could be used in the diagnosis and antibodies based vaccines.5 
Anti-gp70	antibodies	are	potentially	useful	for	disease’s	therapy	be-
cause	they	strongly	reduce	the	host	fungal	burden,	thus	preventing	
Sporothrix	 adhesion	 to	 the	extracellular	matrix	components,	or	 in-
ducing	the	yeasts	opsonization	in	the	host-pathogen	interaction.126 
The need to develop new antifungal drugs is encouraged by 
the increasing number of refractory cases resulting from the emer-
gence of the resistance phenotype among the etiological agents.127 
Currently,	researches	on	alternative	treatments	for	sporotrichosis	re-
veal	promising	molecules,	such	as	terpinen-4-ol	and	farnesol,	milte-
fosine,	TCAN26	(a	structural	analogous	of	miltefosine)	and	the	H3	
molecule	(an	inhibitor	of	the	sterol	methyltransferase	enzyme).127-131 
However,	 it	 should	be	pointed	out	 that	 it	 is	 still	necessary	 to	use	
appropriate animal models and clinical tests to ensure the effective-
ness and safety of treatment for such alternatives. q
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Table 2: Main drugs used in sporotrichosis treatment with the corresponding dosages  
Drug Itraconazole1 100 mg capsules Terbinafine	125	and	250mg	tablets Potassium  solution
Continuous Pulse Continuous Pulse 1.42g/mL	(0.07g/drop)
Adult 100-400mg/d2 400mg/d 250-500mg/d4 500mg/d 2- 4g/d
7d/month 7d/month
Pediatric 3-5mg/Kg/d3 ------ 62.5	–	250	mg/d5 ---- 1-2 g/d
Dosage 1-2 x/d 2x/d 1-2 x/d 1-2 x/d 2 x/d
Laboratory control6 Blood	count,	biochemistry,	LFT Blood	count,	biochemistry,	LFT
Blood	count,	biochemistry,	
LFT,	TSH,	T4L
1 Take	at	mealtime;	2	Start	at	100mg/d;	3	Maximum	of	200mg/d;	4Start	at	250mg/d;	5Dose	varies	according	to	weight;	6Prior	to	treatment,	at	3-4	treatment	weeks,	at	the	end	of	the	treatment.	
LFT	-	liver	function	tests	Adapted	from:	Orofino-Costa,	et al. 201570
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Questions 
s
1. The most common clinical presentation of sporotricho-
sis in Brazil is:
 a. lymphocutaneous
 b. fixed	cutaneous
 c. osteoarticular
 d. pulmonary
2. Concerning the sporotrichosis transmission, it may be 
stated that:
 a.  zoonotic	 transmission	only	 takes	place	when	the	etio-
logical agent is Sporothrix globosa
 b.  transmission by means of trauma only happens when 
the etiological agent is S. schenckii
 c.  respiratory transmission results from inhalation of Spo-
rothrix conidia
 d.		respiratory	 transmission	 is	 restricted	 to	 specific	 geo-
graphic regions
3. The histopathological exam in sporotrichosis shows:
 a.	high	sensitivity	and	low	specificity
 b.	low	sensitivity	and	high	specificity
 c. high	sensitivity	and	high	specificity
 d.	low	sensitivity	and	low	specificity
4. To isolate Sporothrix spp. the following basic fungus 
culture media are preferably used:
 a.		Cereal	agar	(Corn	meal	agar)	and	BHI	(Brain	Heart	In-
fusion)
 b.	Mycosel	agar	and	cereal	agar	(Corn	meal	agar)
 c.	Sabouraud	agar	and	PDA	(Potato	Dextrose	Agar)
 d. Sabouraud dextrose agar and Mycosel agar
5. The asteroid body found on the dermis of the patients 
with sporotrichosis:
 a. consists	of	non-specific	inflammatory	cells
 b.	confirms	the	diagnosis	of	sporotrichosis	
 c.  represents a probable immunological reaction to the 
fungal cell
 d.	suggests	the	host’s	immunodeficiency
6. It may be stated that serology for the diagnosis  of spo-
rotrichosis:
 a.	is	only	indicated	for	skin	forms
 b. does not provide a good clinical-laboratory correlation
 c.  is useful in diagnosing systemic and atypical manifesta-
tions
 d.	may	not	be	used	in	organic	fluids	other	than	serum
7. Regarding infectious arthritis caused by Sporothrix spp., 
it is correct to state that:
 a. it is almost always polyarticular and migratory
 b. it is almost always monoarticular with phlogistic signs
 c.	adjacent	skin	lesions	are	not	observed
 d.	it	is	polyarticular,	but	does	not	show	phlogistic	signs
8. Check the true statement regarding the laboratory diag-
nosis of sporotrichosis:
 a.		the	 direct	 microscopy	 is	 more	 sensitive	 and	 specific	
than the culture in humans
 b.		the	gold	standard	is	the	isolation	and	identification	of	
Sporothrix spp.
 c.		the	histopathological	exam,	impregnated	by	silver,	gen-
erally exhibits abundance of fungal structures
 d.  the	 molecular	 identification	 of	 the	 Sporothrix species 
has no diagnostic value.
9. Feline zoonotic sporotrichosis, predominant in the 
South and Southeast regions of Brazil, is mostly associated 
with the following Sporothrix  species:
 a. S. schenckii
 b. S. lurei
 c. S. brasiliensis
 d. S. globosa
10. Examples of immunoreactive sporotrichosis clinical 
forms include:
 a. erythema multiforme and meningitis
 b. Sweet’s syndrome and erythema nodosum
 c. infectious arthritis and erythema multiforme
 d. Sweet’s syndrome and infectious arthritis
11. The choice treatment for localized cutaneous forms of 
sporotrichosis in immunocompetent people is:
 a.	terbinafine
 b.	fluconazole
 c. griseofulvin
 d.	itraconazole
12. Recent advances in Sporothrix taxonomy have led to 
the identification of new clinical interest agents. The clini-
cal clade includes the following species:
 a. S. chilensis,	S. pallida,	S. mexicana,	and	S. globosa
 b. S. brasiliensis,	S. schenckii,	S. chilensis,	and	S. pallida
 c. S. brasiliensis,	S. schenckii,	S. globosa,	and S. luriei
 d. S. schenckii,	S. globosa,	S. mexicana,	and	S. luriei
13. Check the correct alternative regarding potassium io-
dide used in sporotrichosis treatment:
 a.  it is recommended for systemic forms with lung in-
volvement
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 b.  its mechanism of action is well established, inhibiting 
ergosterol synthesis
 c.  it is useful in treating immunoreactive forms due to its 
immunomodulatory effect
 d.  it is used in systemic forms with meningeal involve-
ment
14. Check the alternative that includes the laboratory 
exams to be requested prior to starting treatment with 
itraconazole and as a therapeutic control:
 a. biochemistry, blood count, and liver function tests
 b. liver function tests, blood count, and TSH
 c. blood count, liver function tests, and free T4
 d. biochemistry, liver function tests, and TSH
15. If required, the drug that may be administered to preg-
nant women affected by sporotrichosis is:
 a. fluconazole
 b. itraconazole
 c. amphotericin B
 d. posaconazole
16. Among the actions below, check the one that is not rec-
ommended as a preventive measure against the propaga-
tion of zoonotic transmission sporotrichosis cases:
 a. street animals neutering 
 b. removal of Sporothrix from soil and vegetation
 c. treatment of sick animals
 d. incineration of dead infected animals
17. Among the statements below, check the one in which 
the correlation between the etiological agent and the geo-
graphic distribution is appropriate:
 a. S. brasiliensis in Mexico
 b. S. globosa in Chile
 c. S. pallida in the USA
 d. S. globosa in China
18. The biochemical compound present in S. brasiliensis 
that may be related to its virulence is:
 a. quinine
 b. adrenalin
 c. melanin
 d. erythropoietin
19. The disease most commonly present in the differential 
diagnosis of lymphocutaneous sporotrichosis is:
 a. tegumentary leishmaniasis
 b. granuloma annulare
 c. paracoccidioidomycosis
 d. epidermoid carcinoma
20.  The important biomarker present in the Sporothrix cell 
wall that can be used for the production of a therapeutic 
vaccine is the glycoprotein:
 a. gp40
 b. gp80
 c. gp70
 d. gp100
Answer key
Behçet´s Disease: a review with emphasis on dermatological as-
pects. An Bras Dermatol. 2017;92(4):452-64
1. A
2. C
3. D
4. D
5. C
6. C
7. B
8. B
9. C
10. B
11. D
12. C
13. C
14. A
15. C
16. B
17. D
18. C
19. A
20. C
Papers
Information for all members:  The EMC-D questionnaire 
is now available at the homepage of the Brazilian Annals of 
Dermatology: www.anaisdedermatologia.org.br. The dead-
line for completing the questionnaire is 30 days from the date 
of online publication.
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